title: Pharmacotherapy of eating disorders.
abstract: Eating disorders are complex, chronic disorders that are difficult to treat. In addition, the 2 primary eating disorders, anorexia nervosa and bulimia nervosa, may have acute, life-threatening consequences. Medication trials for eating disorders have been hampered by high dropout rates, high placebo response, short trial duration, insufficient doses, and difficult outcome measures. Only 1 medication has been FDA approved for any eating disorder to date, and that is for fluoxetine in the treatment of bulimia. Clearly, new large-scale, independent studies using novel agents, and studying the use of medications for both short- and long-term outcomes, are needed.
authors.affiliation: University of Alabama, Birmingham, AL 35294-0018, USA. cwj0002@auburn.edu
authors.forename: Cherry Wyant
authors.initials: CW
authors.lastname: Jackson
authors.forename: Marshall
authors.initials: M
authors.lastname: Cates
authors.forename: Raymond
authors.initials: R
authors.lastname: Lorenz
mesh_terms: D000856:Anorexia Nervosa / Q000188:drug therapy* / Q000523:psychology; D000928:Antidepressive Agents / Q000627:therapeutic use*; D052018:Bulimia Nervosa / Q000188:drug therapy* / Q000523:psychology; D003131:Combined Modality Therapy; D006801:Humans; D044623:Nutrition Therapy; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents